HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact
Ryan M. Confer, MS

Ryan M. Confer, MS

President, Chief Executive Officer, Chief Financial Officer

Ryan M. Confer, MS, was appointed to Genprex’s Board of Directors and to President and Chief Executive Officer of Genprex in May 2024. He has also served as our Chief Financial Officer since September 2016. From December 2013 through September 2016, he served as our Chief Operating and Financial Officer, and from June 2011 to December 2013 as our business manager. Mr. Confer has served us in a variety of strategic, operations and finance capacities since our inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee.

Mr. Confer has more than ten years of entrepreneurial experience in planning, launching, developing and growing emerging technology companies. He has served in c-level and vice president roles for a variety early-stage technology companies since 2008. Most notably, Mr. Confer served as VP of Customer Experience and then later as VP of Strategy for KaiNexus, Inc., an emerging technology company that develops continuous improvement software. Prior to his entrepreneurial experiences, Mr. Confer served as a business development consultant for the University of Texas at Austin’s IC2 Institute, an international thinktank and incubator, where he focused on evaluating the commercialization potential of nascent technologies in emerging growth markets. From 2006 to 2009, Mr. Confer served as a portfolio manager for a $500M early-stage technology investment fund.

Mr. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Achievements

  • Serial entrepreneur with more than 10 years of experience in software, medical devices, and biotechnology projects.
  • Experience structuring and negotiating deal terms for financing and licensing transactions.
  • Experience with major U.S. hospital systems to implement continuous improvement processes and systems to improve efficiencies of hospital processes, reduce safety incidents, improve quality and increase financial impact.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes May 7
  • Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma May 6
  • Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting Apr 30
  • Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting Apr 29
Designed and Secured by Barsec
Copyright ©2025 all rights reserved.
Home - Privacy Policy - Terms of Use